



CELL PREPARATION, DELIVERY, AND ADMINISTRATION MANUAL
BLUEROCK THERAPEUTICS, NP








Product Number: MSK-DA01

Protocol Title: Phase 1 Study to Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's Disease

Date: 25 NOV 2020

Version: United States Version 1.0

Approved by:

<small>DocuSigned by:</small>  <small>APR31CT3066249E</small>	11/30/2020 6:01:37 AM PST
 , MBBS Clinical Development BlueRock Therapeutics	Date
<small>DocuSigned by:</small>  <small>APR31CT3066249E</small>	12/1/2020 11:00:00 AM EST
M  , PhD Product Engineering BlueRock Therapeutics	Date
<small>DocuSigned by:</small>  <small>APR31CT3066249E</small>	11/25/2020 1:16:27 PM EST
 , PhD Discovery Bio BlueRock Therapeutics	Date
 MD (<i>Optional</i>) Neurosurgeon Memorial Sloan Kettering	Date

This document may not be used, divulged, or published without consent of BlueRock Therapeutics, NP.

TABLE OF CONTENTS

TABLE OF CONTENTS.....	3
LIST OF FIGURES	4
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.....	5
1. INTRODUCTION	6
1.1. Overview.....	6
1.2. Purpose.....	6
1.3. General Guidance.....	6
2. MSK-DA01 PRODUCT AND DEVICE OVERVIEW	6
2.1. MSK-DA01.....	6
2.1.1. MSK-DA01 Safety and Handling.....	7
2.2. Device	7
Figure 1: Example Package Label of 16-Gauge SmartFlow™ Ventricular Cannula (ClearPoint Neuro).....	7
Figure 2: Sterile, Packaged 16-Gauge SmartFlow™ Ventricular Cannula (ClearPoint Neuro).....	8
3. INVENTORY AND STORAGE OF STUDY SUPPLIES.....	8
3.1. MSK-DA01.....	8
3.2. Device	8
3.2.1. Device Resupply.....	8
3.3. Additional Supplies.....	9
4. MSK-DA01 PRODUCT FORMULATION AND DELIVERY	9
4.1. MSK-DA01 Product Request	9
4.2. Documentation of MSK-DA01 Product Formulation and Delivery.....	9
4.3. Receipt of Formulated MSK-DA01 Product at the Operating Room.....	9
4.4. Preparation and Administration of DA01 Cell product in Operating Room	9
4.5. Formulated MSK-DA01 Product and Device Destruction	24
4.6. MSK-DA01 Cell product Cleanup Procedure	24
4.7. MSK-DA01 Device Complaints	24
5. APPENDICES	25
Appendix 1: Clinical Trial Medical Device Request Form	26
Appendix 2: Clinical Trial Medical Device Receipt Form.....	27



PUBLICATIONS

Neurology | Immunology | Cardiology

NEUROLOGY

Cell Therapies for Parkinson's Disease

2019 - *Clinical and Translational Science* - 12 (2): 95-97

Stefan Irion

Irion presents a summary of Parkinson's disease and cell therapeutic approaches. [Read More »](#)

Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitors Remyelinate the Brain and Rescue Behavioral Deficits following Radiation

2015 - *Cell Stem Cell* - 16 (2): 198-210

Piao, J., Major, T., Auyeung, G., Policarpio, E., Menon, J., Droms, L., Gutin, P., Uryu, K., Tchieu, J., Soulet, D., Tabar, V.

Piao et al illustrate that pluripotent stem cells can be used to derive glial cells (oligodendrocytes) which show significant response benefit in pre-clinical models of radiation brain injury. [Read More »](#)

Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease

2011 - *Nature Letter* - 480: 547-551

Kriks, S., Shim, J., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., Yang, L., Beal, M.F., Surmeier, D.J., Kordower, J.H., Tabar, V., Studer, L.

Kriks et al document pre-clinical model experience in Parkinson's disease, establishing the foundation for translation. [Read More »](#)

Deriving Human ENS Lineages for Cell Therapy and Drug Discovery in Hirschsprung's Disease

2016 - *Nature* - 431 (7592): 105-109